For half a century, the federal government decided how much marijuana could legally be grown in the United States, and the answer was always “a little, for research.” The spring move of state-licensed medical cannabis into Schedule III looked like the end of that era. It isn’t. The DEA has now confirmed that DEA marijuana production quotas will follow medical cannabis into its new legal category, and that a national ceiling on how much can be grown is being built right now.
The confirmation sits inside a routine-looking document: the DEA’s proposed aggregate production quotas for Schedule I and II controlled substances, published in the Federal Register on November 10, 2026 (91 FR 72566, docket DEA-1730P). Most of the notice deals with opioids, stimulants and psychedelics for the coming year. But one section, titled “Quota Requirements for Controlled Substances in Schedule III,” says the agency is working out how much Schedule III marijuana the country legitimately needs and will publish separate quota proposals once it knows. Public comments on the notice are open until December 10, 2026.
Key Takeaways
The DEA has confirmed in writing that state-licensed medical marijuana, now in Schedule III, will be subject to production quotas, but it has not published a single number yet. The agency says it is still choosing the data sources and methods it will use to estimate national medical need, and it will announce proposed quotas in a separate Federal Register notice. Meanwhile, the existing research quotas for Schedule I marijuana stay flat: 6,675,000 grams of marijuana and 1,000,000 grams of marijuana extract are proposed for next year, the same as this year. The reason quotas survive rescheduling is an international treaty, the 1961 Single Convention, which requires countries to cap licensed cannabis production at what legitimate needs justify. For growers and processors, the practical effect is that federal registration will come with a production limit. For patients, nothing changes yet, but the method the DEA picks to count “legitimate need” will eventually shape how much medical cannabis can be produced. Adult-use cannabis remains in Schedule I and outside this system entirely.
What the DEA Marijuana Production Quotas Notice Actually Says
The relevant passage is short and dry, so it helps to translate it. On April 28, 2026, the Acting Attorney General issued a final rule rescheduling FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III. That rule created three new drug codes: 7362 for Schedule III marijuana, 7353 for Schedule III marijuana extract and 7386 for Schedule III naturally derived delta-9-THC. Each code covers only material that is in an FDA-approved product or held under a state medical marijuana license.
The November notice adds three things. First, the DEA says it is registering the manufacturers and distributors who will handle these Schedule III substances. Second, at the same time, it is assessing which datasets are reliable and relevant enough to estimate the country’s legitimate need and production requirements for the three new codes. Third, until that work is finished, the quota table covers only the old Schedule I codes, and the Schedule III numbers will arrive in a separate notice.
That is the whole announcement. There is no figure, no deadline for the follow-up notice and no description of the method. What changed is that the question of whether medical marijuana will face quotas now has an official answer: yes.
Two Different Ceilings: the Research Quota and the Medical Supply Quota
It is easy to mix up two systems that will soon run side by side.
The first is the familiar Schedule I quota. For years, the DEA has set an annual cap on marijuana grown for research and drug development. For next year it proposes to keep every cannabis category at current levels: 6,675,000 grams of marijuana, 1,000,000 grams of marijuana extract, 1,523,040 grams of delta-9-THC and 1,166,130 grams of all other tetrahydrocannabinols. That is about 6.7 metric tons of plant material, a modest amount by commercial standards, and it serves universities, federally registered growers and pharmaceutical developers.
This Schedule I quota does not disappear after rescheduling, because the April rule deliberately left unlicensed bulk marijuana, extracts and THC that has not yet become part of an FDA-approved drug in Schedule I. That keeps the research pipeline under the old rules.
The second system is new. It will cover the cannabis grown, processed and sold under state medical licenses that have entered the federal Schedule III framework. Think of the old quota as a ration for laboratories, and the new one as a ration for an entire medical market. The same notice, for comparison, raises quotas for several psychedelics used in clinical trials, proposing 60,000 grams of psilocybin, 33,296 grams of MDMA and 12,002 grams of ibogaine. Those are research volumes. The Schedule III marijuana quota will have to be counted on a completely different scale.
Why Schedule III Still Means a Cap: the Single Convention
Most Schedule III drugs, such as ketamine or anabolic steroids, do not have production quotas at all. So why does medical marijuana get one?
The answer is the Single Convention on Narcotic Drugs of 1961, which the United States has ratified. Under the treaty, cannabis sits in its strictest category, and the DEA’s notice spells out what follows from that. Manufacturers and distributors must be licensed (Articles 29 and 30), and licensed manufacturers must receive quotas specifying how much they may produce, so that production and stockpiles never exceed what legitimate needs require (Articles 21 and 29).
Moving marijuana between categories of a domestic law does not change its place in an international treaty. That is why the April rule went further than many expected. It also set up a “nominal-price purchase-and-resale mechanism”: registered manufacturers set a nominal price for their marijuana crops, the DEA buys the crops at that price and immediately sells them back to the same company at the same price plus an administrative fee. On paper, this makes a federal agency the sole wholesale buyer of the harvest, which is what Article 23 of the Convention demands. The quota is the second half of the same treaty logic.
How the DEA Calculates a Production Quota
Federal law tells the agency what to weigh. Under 21 U.S.C. 826 and the matching regulation, the Administrator considers the total net disposal of a substance by all manufacturers over the current and two preceding years, trends in that disposal, inventories, projected demand, estimates of diversion, information from the Department of Health and Human Services and the states, and other needs such as raw materials and possible production disruptions.
For opioids and stimulants, the DEA leans heavily on prescription data. In this very notice it explains that the FDA sent predicted domestic medical usage estimates in July, and that the agency buys commercial sales tracking data to anticipate export markets. Medical marijuana has none of that infrastructure. It is not prescribed in the federal sense, there is no national dispensing database, and state programs count patients and sales in different ways.
That is why the line about “assessing data sources and methodologies” matters more than it looks. The likely candidates are obvious: state patient registries, state seed-to-sale tracking systems, sales volumes and physician certifications. Even the simplest of these is large. State registries list roughly 3.9 million registered medical marijuana patients, but registration is voluntary in some states, and others count certifications rather than people. Every choice the DEA makes here will push the national ceiling up or down.
What Quotas Could Mean for Growers and Processors
For state-licensed businesses, the quota will arrive attached to federal registration. The DEA has already started that process. According to a November law-firm analysis by Buchalter, the agency’s list of timely applicants covers 6,983 locations, including more than 4,000 dispensaries, more than 2,000 manufacturers and roughly 700 distributors. The first 900-plus registrations went to dispensaries in seven medical-only states on October 30. Manufacturer applications, meaning cultivators and processors, opened in October and require a facility inspection, production controls and quota determinations, so they are expected to take longer. The details of that rollout, including the November 29 supply-chain deadline, are covered in our guide to DEA medical marijuana registration.
The quota adds a new kind of risk to that paperwork. Under the Single Convention model, an aggregate national quota is usually divided into individual manufacturing quotas. If the DEA follows the same structure it uses for Schedule I and II drugs, each registered cultivator could receive a limit on how much it may produce in a year. The notice does not say this will happen, and the DEA has not described how allocation would work. But it is the obvious template, and it raises hard questions for a market built on state rules rather than federal ones.
State programs were never designed around a national cap. Some states license hundreds of growers, others only a handful. Several have struggled with oversupply, while others have faced shortages. A single federal number would have to be split across dozens of independent markets with very different patient counts, product mixes and growing conditions.
What Quotas Could Mean for Patients
Here the honest answer is that nobody knows yet, because the number that matters has not been proposed.
If the DEA sets the medical quota generously, based on actual sales and registry data, patients may notice nothing at all. If it chooses a narrower measure of need, such as counting only formally certified patients, or applies conservative diversion estimates, production limits could tighten supply in some states. In theory, that could affect product availability and prices. In practice, the effect will depend on details that are still blank: the dataset, the allocation formula, whether quotas can be adjusted mid-year, and how strictly they are enforced.
One thing is clear. Quotas are about how much can be produced, not about what an individual patient may buy. Purchase limits remain a matter of state law. Any effect on patients would be indirect, flowing through supply.
The Questions Nobody Has Answered Yet
The notice drew immediate attention from MMJ International Holdings, a company developing cannabinoid drugs that is participating in a D.C. Circuit challenge to the April rescheduling order. It is an interested party, and its press release should be read as advocacy rather than neutral analysis. Still, the questions it lists are the ones regulators will have to answer.
How will national medical demand be calculated, and from which data: patient registrations, sales, physician recommendations or historical volumes? How will medical use be separated from recreational use and diversion, especially in states that run both markets? Will individual manufacturers receive limits, and on what basis? How will overproduction be prevented across many independent state systems? What happens to state production that exceeds the federal estimate of medical need? The company’s chief executive argues that Wall Street has treated Schedule III as an open door, when in reality it brings a federal production system with its own limits.
There is also a research dimension. As we explained when three experts examined why rescheduling is unlikely to unlock cannabis science on its own, Schedule III status does not automatically give researchers cheaper or easier access to the products patients actually use. A two-track quota system, one for research material in Schedule I and one for state-licensed medicine in Schedule III, may keep those worlds apart for a while longer.
What Happens Next
The immediate step is procedural. Comments on the November 10 notice are due by December 10, 2026, and the DEA will then publish final quotas for the Schedule I and II substances. The Schedule III marijuana proposal will come later in its own notice, which will open its own comment period. That second document is the one to watch, because it should reveal the method as well as the number.
In parallel, the broader question of whether marijuana in general should move to Schedule III remains open. The DEA held an administrative hearing from June 29 through July 15, 2026, and has not issued a decision or a timeline. Until it does, adult-use cannabis stays in Schedule I, outside the registration pathway and outside the new quota system. State laws on recreational use are unaffected; for the current map, see our state-by-state guide to where weed is legal in the US.
The big picture is this: rescheduling did not end federal control over how much medical marijuana is grown. It changed the form of that control. The DEA is now designing the measuring stick, and the first real numbers will tell patients and licensees far more than any announcement so far.
FAQ
Only partly. Since April 28, 2026, two categories are in Schedule III: marijuana in FDA-approved drug products, and marijuana manufactured, distributed or dispensed under a qualifying state medical marijuana license. All other marijuana, including adult-use products, unlicensed bulk material and synthetic THC, remains in Schedule I. A separate DEA proceeding on rescheduling marijuana more broadly has not reached a decision.
For state-licensed medical businesses, it means entering the federal registration system: registering with the DEA, meeting record-keeping and security rules, and, as the DEA has now confirmed, operating under production quotas. Federal tax treatment also changes, because the provision that blocked ordinary business deductions applies only to Schedule I and II substances. For patients, day-to-day access is still governed by state medical cannabis programs.
A production quota is a legal ceiling on how much of a controlled substance may be made in the United States in a year. The DEA sets an aggregate quota for the whole country and can divide it among registered manufacturers. Until now, marijuana quotas covered only research and drug development; the DEA is now preparing separate quotas for state-licensed medical cannabis in Schedule III.
By law, the DEA weighs past disposal of the substance by manufacturers over the current and two preceding years, disposal trends, inventories, projected demand, diversion estimates, and information from federal health agencies and the states. For medical marijuana, the agency says it is still deciding which datasets are reliable enough to estimate legitimate national need.
Legal Disclaimer
This article is for informational and journalistic purposes only and does not constitute legal, regulatory, tax or medical advice. Federal and state cannabis rules are changing quickly, proposed quotas may be revised before they are finalized, and the information above reflects publicly available documents at the time of writing. Businesses and individuals should consult a qualified attorney or compliance professional about their specific circumstances. Cannabis remains a controlled substance under federal law, and its legal status varies by state and by product category.